Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 13, Issue 8, Pages 942-947Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2007.04.007
Keywords
vascular endothelial growth factor; activin-A; allogeneic hematopoietic stem cell transplantation
Categories
Ask authors/readers for more resources
Allogeneic hematopoietic stem cell transplantation is frequently complicated by syndromes characterized by a disruption of the endothelial integrity such as graft-versus-host disease or liver toxicity. Vascular endothelial growth factor and activin-A, a member of the transforming growth factor beta (TGF-beta) superfamily, are important for endothelial integrity and tissue repair. We retrospectively measured endogenous vascular endothelial growth factor and activin-A serum levels in 70 patients following allogeneic stem cell transplantation. Vascular endothelial growth factor serum levels were significantly decreased within the first 2 weeks after the transplant and returned to pre transplant levels by day +15. Activin-A serum levels were significantly elevated from day +7 with peak levels reached on day +10. By using the median value as cutoff high vascular endothelial growth factor levels on day +15 were associated with significantly better overall survival, less liver toxicity, faster neutrophil recovery, and a trend towards less severe acute graft-versus-host disease. No correlation was found between activin-A serum levels and survival, liver toxicity, neutrophil recovery, or graft-versus-host disease. Monitoring of vascular endothelial growth factor levels following allogeneic hematopoietic stem cell transplantation might help to identify patients with a very high risk for early transplant-related complications. (c) 2007 American Society for Blood and Marrow Transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available